LRPPRC gene replacement therapy preserves cardiac function and prevents premature death in a mouse model of mitochondrial disease

Pathogenic variants in LRPPRC disrupt mitochondrial gene expression, causing severe and incurable mitochondrial disease with neurological involvement accompanied by hepatopathy or cardiomyopathy. The development for gene therapy for LRPPRC-linked disease is hindered by the large LRPPRC coding sequence exceeding AAV cargo capacity when combined with classical regulatory elements. Here, we engineered compact single rAAV9 vectors expressing human or mouse LRPPRC and administered them intravenously to heart and skeletal muscle-specific Lrpprc knockout mice. This approach restored cardiac LRPPRC expression, preserved oxidative phosphorylation (OXPHOS) function, prevented cardiomyopathy and markedly extended survival. While skeletal muscle rescue was partial, the therapy effectively prevented fatal cardiac dysfunction. These findings provide the first in vivo proof-of-concept that AAV-mediated LRPPRC gene replacement can preserve OXPHOS function and prevent lethal cardiomyopathy, supporting its potential as a therapeutic strategy for mitochondrial disease linked to LRPPRC deficiency.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-13
DOI
https://doi.org/10.64898/2026.11.12.762002
Primary Topic
Virus-based gene therapy research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

LRPPRC gene replacement therapy preserves cardiac function and prevents premature death in a mouse model of mitochondrial disease

Metodi Dimitrov Metodiev, Agnès Rötig, Sofia Zanin, Clovis Gaborit et al.
3 links
bioRxiv (Cold Spring Harbor Laboratory)
Virus-based gene therapy research
preprint

LRPPRC gene replacement therapy preserves cardiac function and prevents premature death in a mouse model of mitochondrial disease

Metodi Dimitrov Metodiev, Agnès Rötig, Sofia Zanin, Clovis Gaborit, Federico Mingozzi, Gilles Renault, Benedetta Ruzzenente, Franck Lager, Marcelo Simon Sola, Marina Cavazzana
preprint en

Abstract

Pathogenic variants in LRPPRC disrupt mitochondrial gene expression, causing severe and incurable mitochondrial disease with neurological involvement accompanied by hepatopathy or cardiomyopathy. The development for gene therapy for LRPPRC-linked disease is hindered by the large LRPPRC coding sequence exceeding AAV cargo capacity when combined with classical regulatory elements. Here, we engineered compact single rAAV9 vectors expressing human or mouse LRPPRC and administered them intravenously to heart and skeletal muscle-specific Lrpprc knockout mice. This approach restored cardiac LRPPRC expression, preserved oxidative phosphorylation (OXPHOS) function, prevented cardiomyopathy and markedly extended survival. While skeletal muscle rescue was partial, the therapy effectively prevented fatal cardiac dysfunction. These findings provide the first in vivo proof-of-concept that AAV-mediated LRPPRC gene replacement can preserve OXPHOS function and prevent lethal cardiomyopathy, supporting its potential as a therapeutic strategy for mitochondrial disease linked to LRPPRC deficiency.

bioRxiv (Cold Spring Harbor Laboratory)
Hôpital Necker-Enfants Malades (FR), Centre National de la Recherche Scientifique (FR), Inserm (FR), Université Paris Cité (FR), Assistance Publique – Hôpitaux de Paris (FR), Institut Cochin (FR), Institut des Maladies Génétiques Imagine (FR)
Good health and well-being
Virus-based gene therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon